National Reimbursement Drug List (2009): Western Medicines To order this report: Drug_and_Medication Industry : China Regulatory and Market Access Pharmaceutical Report (2013) Contact Clare: clare@reportlinker.
What does NRDL stand for?
NRDL stands for National Reimbursement Drug List (China)
This definition appears very rarely and is found in the following Acronym Finder categories:
- Military and Government
- Science, medicine, engineering, etc.
- Organizations, NGOs, schools, universities, etc.
See other definitions of NRDL
We have 1 other meaning of NRDL in our Acronym Attic
- Natick Research, Development and Engineering Center
- National Reconstruction and Development Fund (Sudan)
- National Rent Deposit Forum (UK)
- National Research and Development Foundation
- Network Rail Discretionary Fund (UK)
- New Republic Defense Force (Star Wars movie military group)
- Nuclear Reaction Data File for Astrophysics (Hokkaido University; Japan)
- Naval Radio Direction Finder Service (US Navy)
- Non-Radiative Dielectric Guide
- Nuclear Reduction Disarmament Initiative
- National Roller Derby League (now International Roller Derby League)
- Naval Radiological Defense Laboratory
- Newcastle Roller Derby League (Australia)
- Navy Recruiting District Los Angeles
- Natural Resources Distance Learning Consortium (Virginia Tech)
- Network-Related Data Management
- NMDA (N-Methyl-D-Aspartate) Receptor Delayed Maturation
- Natural Resources Data Management System (India)
- New Reformed Druids of North America
- Navy Recruiting District New York
Samples in periodicals archive:
The report forecasts that Xarelto and Pradaxa will face obstacles to inclusion on the National Reimbursement Drug List (NRDL) for atrial fibrillation therapy because of the significant increase in treatment costs associated with these agents compared to warfarin.
National Reimbursement Drug List (2009): Western Medicines To order this report: China Regulatory and Market Access Pharmaceutical Report (2013) Contact Clare: clare@reportlinker.
Decision Resources' new Emerging Markets Physician & Payer Forum report entitled Oral Therapies for Type 2 Diabetes - Physician and Payer Perspectives on the Dynamics in the Chinese and South Korean Markets explores the implications of the fact that DPP-IV inhibitors do not currently appear on China's National Reimbursement Drug List (last updated in 2009, prior to the launch of any drug from this class) and therefore experience very low uptake.
Peg-IFN-alpha agents have been included in the 2009 National Reimbursement Drug List in China, with a reimbursement rate that ranges from 50 to 90 percent and varies by region.
We also expect a high uptake of Roche's Xeloda -- an oral pro-drug of 5-fluorouracil (5-FU) -- due to its delivery advantage over intravenous 5-FU and its inclusion on the National Reimbursement Drug List.
Trends -Domestic Chinese Pharmaceutical Companies -- Overview -- Domestic Pharmaceutical Companies' Changing Strategies - Pharmaceutical Distribution in China - Predicted Trends -- Overview -- Healthcare Providers -- Healthcare Funding -- Reimbursement System -- Price Determination -- Regulatory Approvals - Conclusion Appendix A: Recent Acquisitions, Ventures, and Partnerships in the Chinese Drug Industry Appendix B: National Reimbursement Drug List Companies Mentioned: AstraZeneca, Pfizer, Bayer Schering, Roche, Sanofi Aventis, Novartis, GSK, Merck, Novo Nordisk, Eli Lilly, Nycomed, Yangzijiang Pharma, Guangzhou Banyunshan Pharma, North China Pharmaceutical Co.
The report also finds that the anticipated inclusion of Sanofi-Aventis's Taxotere for the treatment of prostate cancer in the next version of the National Reimbursement Drug List (NRDL) will expand the market for this chemotherapy agent by 36% per year.